

Analytical study of some drugs for treatment of neurodegenerative diseases

Thesis presented by
Menna Allah Magdy Mahmoud Youssef

Demonstrator of Pharmaceutical Analytical Chemistry
Faculty of pharmacy - Ain Shams University

B.Sc. in Pharmaceutical Sciences
Faculty of pharmacy - Ain Shams University
2011

Submitted for the partial fulfillment of
Master Degree in Pharmaceutical Sciences
(Pharmaceutical Analytical Chemistry)

Under the Supervision of:

Prof. Dr. Maha Farouk Abd El-Ghany
Professor of Pharmaceutical Analytical Chemistry
Dean of
Faculty of Pharmacy - Ain Shams University

Prof. Dr. Lobna Abd El-Aziz Hussein
Professor and Head of Pharmaceutical Analytical Chemistry Department
Faculty of Pharmacy - Ain Shams University

Associate Prof. Dr. Miriam Farid Ayad
Associate Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy - Ain Shams University

Pharmaceutical Analytical Chemistry Department
Faculty of Pharmacy - Ain Shams University
2018

Acknowledgment

All the thanks and gratitude is to my Lord ALLAH, who has given me the will and strength to finish this work. Words and thanks will never suffice to praise ALLAH for his blessings I have and granting me patience, guidance and wonderful people around helping and supporting me.

I was lucky to have outstanding supervisors. It's my great pleasure to express my sincere thanks and appreciation to **Prof. Dr. Maha Farouk Abd El-Ghany**, Professor of Pharmaceutical Analytical Chemistry, Dean of Faculty of Pharmacy Ain Shams University. For being a caring mother and a dedicated professor, for her expert supervision, constructive comments, generous assistance and guidance during the supervision of this work. I will always be indebted to her kindness and continuous support.

Words are not enough to express my deep thanks and gratitude to **Prof. Dr. Lobna Abd El-Aziz Hussein**, Professor and Head of Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, who taught me generously and whom I am proud to be one of her students, for her kind supervision, continuous encouragement, sincere guidance, endless support throughout my life and her belief in me which always gives me the courage to go forward.

I would like to express my gratefulness and appreciation for **Associate Prof. Dr. Miriam Farid Ayad**, Associate Professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, for her kind supervision, continuous encouragement, indispensable advice, sincere guidance, constructive criticism, valuable comments, endless support throughout my work in this thesis and in my professional career. I wish her every success in her life and work.

No words can express how I feel and my gratitude to my parents and role model **Prof. Dr. Magdy Mahmoud Youssef** and **Prof. Dr. Mona Moussa**, after ALLAH, I owe them everything. Actually without their love, endless support, solid faith in me, continuous support and encouragement, this work would have never been accomplished. I would also like to thank my brothers, **Mohi** and **Mazen**, for supporting me all the way and for always being willing to help. I would like to thank my whole family and friends.

I am also thankful to my dear husband, **Dr. Ahmed Mohamed Mahmoud**, for standing by my side, believing in me, helping and encouraging me that had made my continuation in the hard times attainable. Also, my son **Khaled**, the fruit of my life, I love him so much, and I would like him to be always proud of me as I am of him.

Finally, my sincere appreciation and thanks goes to all my colleagues and staff members in Pharmaceutical Analytical Chemistry, for their friendly cooperation and constant support.

Menatallah Youssef
2018

List of Abbreviations

ATR-FTIR	Attenuated total reflectance Fourier transform infrared
B.N.	Batch number
CA	Chronoamperometry
CMC	Carboxy methyl cellulose
CNS	Central nervous system
COMT	Catechol-O-methyltransferase
CV	Cyclic voltammetry
°C	Degree Celsius
D ₀	Zero order absorption spectra
D ₂	Second derivative absorption spectra
D ₄	Fourth derivative absorption spectra
DA	Dopamine
DD	Double divisor
DD ¹	First derivative of the ratio spectra
DDRD	Double divisor ratio spectra derivative
DMF	Dimethylformamide
DPV	Differential pulse voltammetry
DRZC	Derivative ratio spectra zero crossing
DZC	Derivative zero crossing
HETP	Height Equivalent to Theoretical Plate
HILIC	Hydrophilic interaction liquid chromatography
HPLC	High performance liquid chromatography
ICH	International Conference on Harmonization
K'	Capacity factor
LBs	Lewy bodies
LC-MS	Liquid chromatography-Mass Spectroscopy
LOD	Limit of Detection
LOQ	Limit of Quantitation
MAO-B	Monoamine oxidase B
MC	Mean center
MCR	Mean centering ratio spectra
min	Minute
N	Theoretical Plate
NMR	Nuclear magnetic resonance
PCR	Principal Component Regression
PD	Parkinson's disease
PLS	Partial Least Squares
RMSEC	Root mean square error of calibration
RMSECV	Root mean square error of cross validation

RMSEP	Root mean square error of prediction
RP	Reversed phase
R _s	Resolution
% R	Percentage recovery
RSD	Relative standard deviation
SD	Standard deviation
SDS	Sodium dodecyl sulfate
SFS	Synchronous fluorescence spectroscopy
SN	Substantia nigra
SWV	Square wave voltammetry
T	Tailing Factor
TLC	Thin layer chromatography
UPLC	Ultra performance liquid chromatography
UV	Ultra violet
UV/ Vis	Ultra violet/ Visible
A	Selectivity factor
$\Delta\lambda$	Spectral bandwidth
λ_{em}	Emission wavelength
λ_{ex}	Excitation wavelength

CONTENTS

List of figures	x
List of tables	xiv
Summary.....	xviii

PART I: Introduction and Literature Review

Section A General Introduction

	Page
I.A.1. Neurodegenerative diseases	1
I.A.2. Parkinson's disease etiology.....	1
I.A.3. Parkinson's disease clinical features.....	2
I.A.4. Parkinson's disease management.....	3

Section B Literature Review

I.B.1. Chemical structure and physicochemical properties.....	6
I.B.1.1. Levodopa.....	6
I.B.1.2. Carbidopa.....	6
I.B.1.3. Entacapone.....	7
I.B.2. Methods of Analysis.....	7
I.B.2.1. Spectroscopic techniques.....	8
I.B.2.2. Separation techniques	11
I.B.2.2.1. Thin Layer Chromatography	11
I.B.2.2.2. High Performance Liquid Chromatography.....	11
I.B.2.2.3. Ultra performance Liquid Chromatography.....	20
I.B.2.2.4. Hydrophilic Interaction Liquid Chromatography.....	20

I.B.2.2.5. Electrophoresis.....	21
I.B.2.3. Electrochemical techniques.....	24

PART II: Spectrophotometric Methods for Determination of Antiparkinsonian Drugs Levodopa, Carbidopa and Entacapone

Section A

Derivative Ratio Spectra Zero Crossing Method for Determination of Entacapone in the presence of Levodopa and Carbidopa

II.A.1. Introduction.....	30
II.A.2. Experimental.....	31
II.A.2.1. Instrumentation.....	31
II.A.2.2. Samples.....	31
II.A.2.3. Chemicals and reagents.....	31
II.A.2.4. Standard solutions.....	31
II.A.2.5. Procedure.....	32
II.A.2.5.1. Spectral characteristics of Levodopa, Carbidopa and Entacapone	32
II.A.2.5.2. Method validation.....	32
II.A.2.5.2.1. Linearity.....	32
II.A.2.5.2.2. Accuracy.....	33
II.A.2.5.2.3. Specificity.....	33
II.A.2.5.2.4. Precision.....	33
II.A.2.5.2.5. Limit of detection (LOD) and limit of quantitation (LOQ).....	33
II.A.2.5.3. Application to the pharmaceutical preparation	34
II.A.3. Results and Discussion.....	34

Section B

Double Divisor Ratio Spectra Derivative Method for Simultaneous Determination of Levodopa, Carbidopa and Entacapone

II.B.1. Introduction.....	44
II.B.2. Experimental.....	45
II.B.2.1. Instrumentation.....	45
II.B.2.2. Samples.....	45
II.B.2.3. Chemicals and reagents.....	45
II.B.2.4. Standard solutions.....	45
II.B.2.5. Procedure.....	46
II.B.2.5.1. Spectral characteristics of Levodopa, Carbidopa and Entacapone	46
II.B.2.5.2. Method validation.....	46
II.B.2.5.2.1. Linearity.....	46
II.B.2.5.2.2. Accuracy.....	47
II.B.2.5.2.3. Specificity.....	47
II.B.2.5.2.4. Precision.....	47
II.B.2.5.2.5. Limit of detection (LOD) and limit of quantitation (LOQ).....	47
II.B.2.5.3. Application to the pharmaceutical preparation	48
II.B.3. Results and Discussion.....	48

Section C

Mean Centering Ratio Spectra Method for Simultaneous Determination of Levodopa, Carbidopa and Entacapone

II.C.1. Introduction.....	62
II.C.2. Experimental.....	63
II.C.2.1. Instrumentation.....	63
II.C.2.2. Samples.....	64

II.C.2.3. Chemicals and reagents.....	64
II.C.2.4. Standard solutions.....	64
II.C.2.5. Procedure.....	64
II.C.2.5.1. Spectral characteristics of Levodopa, Carbidopa and Entacapone	64
II.C.2.5.2. Method validation.....	64
II.C.2.5.2.1. Linearity.....	64
II.C.2.5.2.2. Accuracy.....	65
II.C.2.5.2.3. Specificity.....	65
II.C.2.5.2.4. Precision.....	65
II.C.2.5.2.5. Limit of detection (LOD) and limit of quantitation (LOQ).....	66
II.C.2.5.3. Application to the pharmaceutical preparation	66
II.C.3. Results and Discussion.....	66

PART III: Determination of the Studied Antiparkinsonian Drugs by Spectrofluorimetric Methods

Section A

Derivative Zero Crossing (DZC) Synchronous Spectrofluorimetry for Simultaneous Determination of Levodopa and Carbidopa

III.A.1. Experimental.....	82
III.A.1.1. Instrumentation.....	82
III.A.1.2. Samples.....	82
III.A.1.3. Chemicals and reagents.....	82
III.A.1.4. Standard solutions.....	83
III.A.1.5. Procedures.....	83
III.A.1.5.1. Spectral characteristics of Levodopa and Carbidopa	83

III.A.1.5.2. Optimization of the assay method.....	84
III.A.1.5.3. Method validation.....	85
III.A.1.5.3.1. Linearity.....	85
III.A.1.5.3.2. Accuracy.....	86
III.A.1.5.3.3. Specificity.....	86
III.A.1.5.3.4. Precision.....	87
III.A.1.5.3.5. Limit of detection (LOD) and limit of quantitation (LOQ).....	87
III.A.1.5.4. Application of the proposed method for the determination of Levodopa and Carbidopa in combined dosage form	88
III.A.2. Results and Discussion.....	88

Section B

Fluorescence Quenching Method for Determination of Entacapone

III.B.1. Introduction.....	106
III.B.2. Experimental.....	106
III.B.2.1. Instrumentation.....	106
III.B.2.2. Samples.....	106
III.B.2.3. Chemicals and reagents.....	107
III.B.2.4. Standard solutions.....	107
III.B.2.5. Procedure.....	107
III.B.2.5.1. Spectral characteristics of anthracene alone and in the presence of Entacapone	107
III.B.2.5.2. Method validation.....	107
III.B.2.5.2.1. Linearity.....	107
III.B.2.5.2.2. Accuracy.....	108
III.B.2.5.2.3. Precision.....	108
III.B.2.5.2.4. Limit of detection (LOD) and limit of quantitation (LOQ).....	108

III.B.2.5.3. Application of the proposed method for the determination of ENT in pharmaceutical dosage form	109
III.B.3. Results and Discussion.....	109

PART IV: Chemometric Principal Component Regression (PCR) and Partial Least Square (PLS) Methods for Simultaneous Determination of Levodopa, Carbidopa and Entacapone

IV.1. Introduction.....	119
IV.2. Experimental.....	120
IV.2.1. Instrumentation.....	120
IV.2.2. Samples.....	120
IV.2.3. Chemicals and reagents.....	120
IV.2.4. Standard solutions.....	120
IV.2.5. Procedures.....	120
IV.2.5.1. Spectral characteristics of Levodopa, Carbidopa and Entacapone	120
IV.2.5.2. Calibration and Validation Sets.....	121
IV.2.5.3. Application to the pharmaceutical formulation.....	121
IV.3. Results and Discussion.....	122

PART V: High Performance Liquid Chromatographic Method for Simultaneous Determination of Levodopa, Carbidopa and Entacapone in Ternary Mixture, Pharmaceutical Formulations and Biological Fluids

V.1. Introduction.....	138
V.2. Experimental.....	138
V.2.1. Instrumentation.....	138
V.2.2. Pure Samples.....	139

V.2.3. Chemicals and reagents.....	139
V.2.4. Standard solutions.....	139
V.2.5. Procedures.....	139
V.2.5.1. Chromatographic conditions.....	140
V.2.5.2. Method validation.....	140
V.2.5.2.1. Linearity.....	140
V.2.5.2.2. Accuracy.....	140
V.2.5.2.3. Specificity.....	141
V.2.5.2.4. Precision.....	141
V.2.5.2.5. Robustness.....	141
V.2.5.2.6. Limit of detection (LOD) and limit of quantitation (LOQ).....	142
V.2.5.3. Application.....	142
V.2.5.3.1. Application to pharmaceutical preparations.....	142
V.2.5.3.2. Application in biological fluids.....	143
V.3. Results and Discussion.....	144

PART VI

General Discussion

VI. General discussion.....	170
-----------------------------	-----

References

VII. References.....	175
----------------------	-----

Arabic Summary

List of Figures

No.	Title	Page
1	Zero order absorption spectra of Entacapone, Levodopa and Carbidopa.	38
2	First derivative of the ratio spectra of Entacapone and Levodopa using Carbidopa as divisor.	38
3	Calibration curve correlating peak amplitude to the corresponding concentration of Entacapone by derivative ratio spectra zero crossing method.	39
4	First derivative of the ratio spectra for the lab prepared mixtures of Entacapone with different ratios to Levodopa and Carbidopa divided over Carbidopa as a best divisor.	39
5	First derivative of the ratio spectra of Levodopa using a binary mixture of Carbidopa and Entacapone as double divisor.	52
6	First derivative of the ratio spectra of Carbidopa using a binary mixture of Levodopa and Entacapone as double divisor.	52
7	First derivative of the ratio spectra of Entacapone using a binary mixture of Levodopa and Carbidopa as double divisor.	53
8	Calibration curve correlating peak amplitude to the corresponding concentration of Levodopa by double divisor-ratio spectra derivative method.	53
9	Calibration curve correlating peak amplitude to the corresponding concentration of Carbidopa by double divisor-ratio spectra derivative method.	54
10	Calibration curve correlating peak amplitude to the corresponding concentration of Entacapone by double divisor-ratio spectra derivative method.	54
11	First derivative of the ratio spectra for the lab prepared mixtures of Levodopa with different ratios to Carbidopa and Entacapone divided over Carbidopa and Entacapone.	55
12	First derivative of the ratio spectra for the lab prepared mixtures of Carbidopa with different ratios to Levodopa and Entacapone divided over Levodopa and Entacapone.	55
13	First derivative of the ratio spectra for the lab prepared mixtures of Entacapone with different ratios to Levodopa and Carbidopa divided over Levodopa and Carbidopa.	56

14	The mean centered second ratio absorption spectra of Levodopa.	70
15	The mean centered second ratio absorption spectra of Carbidopa.	70
16	The mean centered second ratio absorption spectra of Entacapone.	71
17	Calibration curve correlating peak amplitude to the corresponding concentration of Levodopa by mean centering of ratio spectra method.	71
18	Calibration curve correlating peak amplitude to the corresponding concentration of Carbidopa by mean centering of ratio spectra method.	72
19	Calibration curve correlating peak amplitude to the corresponding concentration of Entacapone by mean centering of ratio spectra method.	72
20	The mean centered of second ratio absorption spectra for the lab prepared mixtures of Levodopa with different ratios to Carbidopa and Entacapone.	73
21	The mean centered of second ratio absorption spectra for the lab prepared mixtures of Carbidopa with different ratios to Levodopa and Entacapone.	73
22	The mean centered of second ratio absorption spectra for the lab prepared mixtures of Entacapone with different ratios to Levodopa and Carbidopa.	74
23	3D fluorescence scan spectra of Levodopa	94
24	3D fluorescence scan spectra of Carbidopa	94
25	Excitation spectra of each of Levodopa and Carbidopa	95
26	Emission spectra of each of Levodopa and Carbidopa	95
27	Synchronous fluorescence spectrum of each of Levodopa and Carbidopa	96
28	Effect of different $\Delta\lambda$ on fluorescence of Levodopa	96
29	Effect of different $\Delta\lambda$ on fluorescence of Carbidopa	97
30	Effect of addition of different diluents on relative fluorescence intensity of Levodopa and Carbidopa	97
31	Effect of addition of different organized media on relative fluorescence intensity of Levodopa and Carbidopa	98
32	Effect of addition of different buffers & different pH values on relative fluorescence intensity of Levodopa and Carbidopa	98
33	Second derivative synchronous spectrum of Levodopa.	99

34	Fourth derivative synchronous spectrum of Carbidopa.	99
35	Calibration curve correlating peak amplitude to the corresponding concentration of Levodopa by derivative zero crossing method.	100
36	Calibration curve correlating peak amplitude to the corresponding concentration of Carbidopa by derivative zero crossing method.	100
37	Second derivative synchronous spectrum for the lab prepared mixtures of Levodopa with different ratios to Carbidopa.	101
38	Fourth derivative synchronous spectrum for the lab prepared mixtures of Carbidopa with different ratios to Levodopa.	101
39	3D fluorescence scan spectrum of Entacapone	113
40	Synchronous fluorescence spectra of anthracene alone and in the presence of various concentrations of Entacapone.	113
41	3D fluorescence scan spectrum of anthracene	114
42	Excitation and emission spectra of anthracene.	114
43	Effect of different $\Delta\lambda$ on fluorescence of anthracene	115
44	Calibration curve correlating (F^0/F) to the corresponding concentration of Entacapone by fluorescence quenching method.	115
45	RMSEC plot of the cross validation results of the training set used to construct the Principal Component Regression calibration of Levodopa, Carbidopa and Entacapone.	125
46	RMSEC plot of the cross validation results of the training set used to construct the Partial Least Square -2 calibration of Levodopa, Carbidopa and Entacapone.	125
47	Residual versus actual concentrations plot for Levodopa, using the Principal Component Regression method.	126
48	Residual versus actual concentrations plot for Carbidopa, using the Principal Component Regression method.	126
49	Residual versus actual concentrations plot for Entacapone, using the Principal Component Regression method.	127
50	Residual versus actual concentrations plot for Levodopa, using the Partial Least Square-2 method.	127
51	Residual versus actual concentrations plot for Carbidopa, using the Partial Least Square-2 method.	128
52	Residual versus actual concentrations plot for Entacapone, using the Partial Least Square-2 method.	128

53	Linearity of predicted concentration versus the actual one plot for Levodopa, using the Principal Component Regression method.	129
54	Linearity of predicted concentration versus the actual one plot for Carbidopa, using the Principal Component Regression method.	129
55	Linearity of predicted concentration versus the actual one plot for Entacapone, using the Principal Component Regression method.	130
56	Linearity of predicted concentration versus the actual one plot for Levodopa, using the Partial Least Square-2 method.	130
57	Linearity of predicted concentration versus the actual one plot for Carbidopa, using the Partial Least Square-2 method.	131
58	Linearity of predicted concentration versus the actual one plot for Entacapone, using the Partial Least Square-2 method.	131
59	HPLC Chromatogram showing simultaneous separation of Levodopa, Carbidopa and Entacapone.	151
60	Calibration curve correlating peak area to the corresponding concentration of Levodopa by HPLC method.	151
61	Calibration curve correlating peak area to the corresponding concentration of Carbidopa by HPLC method.	152
62	Calibration curve correlating peak area to the corresponding concentration of Entacapone by HPLC method.	152
63	HPLC Chromatogram showing separation of Levodopa, Carbidopa and Entacapone in <i>Stalevo</i>® tablets.	153
64	HPLC Chromatogram showing separation of Levodopa and Carbidopa in <i>Sinemet</i>® tablets.	153
65	HPLC Chromatogram showing Entacapone in <i>Parkicapone</i>® tablets.	154
66	HPLC Chromatogram of blank urine sample.	154
67	HPLC Chromatogram of urine sample spiked with Levodopa , Carbidopa and Entacapone.	155
68	HPLC Chromatogram of blank plasma sample.	155
69	HPLC Chromatogram of plasma sample spiked with Levodopa and Entacapone.	156